Sandra Koseoglu
Director/ Program Lead, Clinical Sciences and Study Management
Merck
Sandra Koseoglu, ACRP-CP, is a Director in Clinical Science and Study Management at Merck, where she leads enterprise‑level efforts to simplify clinical trial processes through automation, risk‑proportionate approaches, and alignment with ICH E6(R3). She serves as the global process lead for Protocol Deviations, driving modernization of governance, oversight, and analytics to reduce manual burden while strengthening inspection readiness and trial quality. She also serves as a Program Lead in CSSM, supporting complex development programs from protocol design through execution and regulatory filing. Her current work focuses on embedding quality by design, automation, and AI‑enabled insights into clinical operations to support more efficient, compliant, and patient‑focused trials. Sandra has over 25 years of experience in pharma and biotech and brings end‑to‑end experience across the drug development lifecycle, including prior roles as a research scientist in target and drug discovery spanning Oncology, Cardiology, Infectious Diseases, and Vaccines.